Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.

• Revenue in USD (TTM)4.40m
• Net income in USD-60.78m
• Incorporated2009
• Employees46.00

• Location
  Insight Molecular Diagnostics Inc2 International Plaza Dr., Suite 510NASHVILLE 37217United StatesUSA
• Phone+1 (949) 409-7600
• Fax+1 (510) 521-3389
• Websitehttps://imdxinc.com/